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The gonadotrophin hormones, follicle stimulating hormone and luteinising hormone, are 24 
essential for reproduction. They work in concert to control multiple aspects of gonadal function 25 
to ultimately produce meiotically competent and fertilisable gametes, provide the optimal 26 
endometrial environment and support for implantation and maintain pregnancy via 27 
progesterone production throughout the first trimester of pregnancy. These complex and 28 
multidimensional functions are mediated via the gonadotrophin hormone receptors, luteinising 29 
hormone receptor (LHR) and follicle stimulating hormone receptor (FSHR), Class A G protein-30 
coupled receptors (GPCR), which couple to multiple G protein-dependent and independent 31 
signal pathways to control these physiological processes. Over the last two decades, a 32 
plethora of experimental evidence has shown that GPCRs can associate to form dimers and 33 
oligomers. This association provides a means of mediating the diverse functional 34 
requirements of a single receptor subtype and for the gonadotrophin hormone receptors, has 35 
been shown to alter the pharmacology and signal activation profile of these receptors. This 36 
review will detail the historical and current evidence detailing the formation of gonadotrophin 37 
hormone receptor homomers and heteromers. We will discuss the functional insight gained 38 
from in vitro and in vivo studies, and the potential impact in modulating reproductive health 39 









1. Introduction 49 
The coordinated actions of receptor-mediated processes ensure the correct functioning of all 50 
physiological and endocrine processes. This is particularly pertinent for the gonadotrophin 51 
hormone receptors (GpHRs), follicle-stimulating hormone receptor (FSHR) and luteinising 52 
hormone receptor (LHR), whose actions are essential for reproduction and fertility(1-3). 53 
Localised to specialised cellular compartments of the testes and ovaries, the GpHRs control 54 
and regulate gonadal functions; in males, regulating testosterone production and the 55 
proliferation and maturation of sperm(1), and in females, regulating gonadal steroidogenesis, 56 
follicular growth and maturation, follicle recruitment and dominant follicle selection, ovulation, 57 
and corpus luteum function(2,3). Due to the importance of GpHRs in initiating and maintaining 58 
fertility, they are key targets of assisted reproductive technologies, particularly in vitro 59 
fertilisation (IVF). Additionally, in recent years, the extragonadal expression of GpHRs has 60 
been reported, with proposed roles in prostate cancer(4), placental function(5,6), osteoclast 61 
activity(7,8), thermiogenesis(9) and the development of Alzheimer’s disease(10). Thus, 62 
understanding the mechanisms underpinning how GpHRs function is imperative for the 63 
generation of more efficacious, targeted, effective and potentially personalised 64 
pharmacological-based therapeutic strategies for improvements in reproductive health, and 65 
also non-reproductive health and disease. This review will discuss a concept that has emerged 66 
over the last two decades as an important modality for regulating GpHR function, namely, the 67 
formation of GpHRs dimers and oligomers. We will first briefly appraise the functional roles of 68 
di/oligomerisation for the wider G protein-coupled receptors superfamily, before delving into 69 
the evidence presented for GpHR di/oligmerisation, and the impact on GpHR function. We will 70 
finish with discussing pertinent and outstanding questions in our GpHR di/oligomerisation and 71 
future perspectives for this important area of research. 72 
 73 
 74 
2. Why do GpHR di/oligomerisation? 75 
For many years, the accepted central dogma for how GPCRs functioned, was as a single 76 
receptor unit, binding hormone and mediating activation of a linear, single G protein-77 
dependent signal pathway. However, an explosion of literature over the last 20-30 years has 78 
questioned this idea and presented evidence that this view of GPCR signalling was perhaps, 79 
unsurprisingly, too simplistic. Indeed, most GPCRs, including the GpHRs, can couple to more 80 
than 1 G protein-dependent signal pathway, may have more than 1 endogenous ligand, and 81 
can activate non-G protein-dependent pathway activation via recruitment of the molecular 82 
scaffolding protein, -arrestin (recently reviewed in (11-13)). In addition, more recent studies 83 
have added additional layers to this complexity with internalised GPCRs, including the 84 
luteinising hormone receptor(14), and closely related the thyroid stimulating hormone 85 
receptor(15,16), able to sustain cAMP-dependent signalling from the endosome(17,18).  The 86 
complex requirements of a single GPCR subtype show the diverse modalities that GPCRs 87 
need to exploit to mediate their physiological effects. A concept that has emerged as 88 
increasingly important mode of regulating GPCRs functionality, is receptor dimerisation and 89 
oligomerisation. The association of GPCRs, including the GpHRs, with self (homomerisation) 90 
or with other GPCRs (heteromerisation) has been shown to occur, providing a platform to 91 
regulate different aspects of a GPCRs lifecycle(19), and afford the ability to diversify functional 92 
responses, regulate the magnitude of signal response, the specificity of signal produced and 93 
ligand directed biased signalling(11,12,20).   94 
 95 
Although studies have shown that GPCRs, including FSHR and LHR can di/oligomerise, most 96 
information has been derived from heterologous cell systems over-expressing receptors, 97 
therefore, the significance in health and disease remains largely unclear. Innovative 98 
approaches to study the GpHR di/oligomerisation have pushed forward our understanding of 99 
the physiological relevance of Class A GPCR di/oligomerisation, showing its role and 100 
relevance to regulating GpHR function, in vivo.  101 
3. Biochemical and biophysical evidence of gonadotrophin receptor dimerisation 102 
The first suggestion or inference that GpHR could associate, originated from the electron 103 
microscopy studies of the 1970’s and 1980’s. Using ovarian theca and granulosa cells and 104 
binding of labelled hCG to LHR, showed that LHR existed as ‘clusters’(21,22). The proposed 105 
clustering of LHR on hCG binding was suggested to stagnate the receptors, thereby 106 
minimising the lateral diffusion of receptors, to negatively regulate G protein-coupling(22).  In 107 
more recent years, this concept has been further explored using time-resolved 108 
phosphorescence anisotropy, a biophysical technique that can track the movement of LHR 109 
within the plasma membrane. Utilising endogenous LHR expression in the Leydig tumour cell 110 
line, MA-10 cells, and ovine luteal cells, binding of hCG to LHR, was shown to rotationally 111 
immobilise LHR, the result of increased LHR-LHR interactions induced by ligand binding. This 112 
suggested the presence of a ligand-induced increase in LHR clustering into specialised micro-113 
domains, and potentially association to form homomers(23,24). This ‘clustering’ could of 114 
course be attributed to the initial steps in receptor desensitisation processes, and clustering 115 
into clathrin coated pits for receptor internalisation, in line with classical Class A GPCR 116 
endocytosis on ligand binding(17,18). More recent studies of LHR suggest that internalisation 117 
kinetics and routing fate of LHR (and FSHR) are different to more typical Class A GPCRs, 118 
such as 2 adrenergic receptor, (25,26), with LHR (and FSHR) trafficking to a newly identified 119 
and smaller endosomal compartment- the very early endosome. However, how 120 
di/oligomerisation of LHR (and FSHR) links with internalisation to endosomal compartments 121 
remains to be determined. Interestingly, the rotational diffusion rate of LHR was different when 122 
bound to LH and hCG, suggesting potential differential regulation of LHR clustering and 123 
potentially homomerisation by these two hormones(23).  124 
 125 
Co-immunoprecipitation of differentially epitope-tagged LHR and FSHR provided some of the 126 
first biochemical evidence supporting the formation of LHR and FSHR dimers and oligomers.  127 
Initially Western blotting of single tagged LHR showed varying molecular weight LHR species, 128 
suggesting the presence of LHR monomers, dimers and oligomers in whole cell lysates(27). 129 
To confirm that the larger dimeric and oligomeric bands were formed from interacting LHR 130 
protomers, co-immunoprecipitation of two differentially tagged-LHR was carried out, showing 131 
the presence of higher molecular forms of LHR and supporting the hypothesis that LHR does 132 
form dimeric and higher order oligomeric LHR. Interestingly, hCG dose dependently increased 133 
the number of LHR dimers and oligomers observed, but only when the LHR was stably 134 
expressed, and therefore efficiently trafficked to the membrane in its mature post-135 
translationally modified form(27). As co-immunoprecipitations analyse whole cell fractions, it 136 
is likely that this reflects differences in plasma membrane versus intracellular endoplasmic 137 
reticulum localised LHR, and the differences in cellular localisation of LHR that stable versus 138 
transient transfection of LHR results in(27). Latter studies utilising the proximity-based 139 
resonance energy transfer technique of bioluminescence energy transfer (BRET), confirmed 140 
the association of LHR into dimers/oligomers, and demonstrated the specificity of this 141 
interaction. Interestingly, ligand treatment was shown to have no effect on LHR association 142 
via this method(28).  143 
 144 
Direct biochemical evidence for the formation of FSHR homomers was also achieved using a 145 
combination of co-immunoprecipitation, FRET and BRET techniques. Similarly, to findings 146 
with the LHR, FSHR was shown to reside as monomers, dimers and oligomeric 147 
complexes(29,30), with FSH treatment having little effect on the relative ratios of FSHR 148 
monomers, dimers and oligomers,  formed, in concordance with later BRET studies and single 149 
molecule imaging studies of LHR dimers and oligomers(31).  150 
 151 
The subcellular location and timing of GpHR homomer formation has been identified. Using a 152 
combination of co-immunoprecipitation with subcellular fractionation and BRET techniques 153 
LHR and FSHR dimers and oligomers were shown to be localised to the plasma membrane 154 
and endoplasmic reticulum(29).  Moreover, utilisation of a misfolded mutant LHR that was 155 
shown to be retained in the ER, revealed association of wild type LHR with the misfolded ER 156 
retained mutant LHR, showing that LHR dimers and oligomers were formed during the post-157 
translational processing and modification of LHR within the ER. Analogous studies to 158 
investigate this question with FSHR, showed FSHR dimers and oligomers were also formed 159 
in the ER following translation. 160 
 161 
4. GpHR di/oligomerisation and functional asymmetry 162 
A debated and remaining question in GPCR di/oligomer field is how ligand binding within a 163 
dimer or oligomer impacts on subsequent ligand binding to additional receptor protomers 164 
within a complex. An elegant study by Urizar et al(32), provided the link between glycoprotein 165 
hormone receptor di/oligomerisation, and negative cooperativity, via BRET and competition 166 
binding assays. To explore the effect of ligand binding within a dimer on subsequent ligand 167 
bindings to additional receptor protomers within a complex, a chimeric receptor of the LHR 168 
extracellular domain fused to the transmembrane region of the TSHR was generated.  When 169 
the full length, wild type TSHR was expressed alone and binding assays conducted, as 170 
expected, hCG failed to compete with TSH for binding to TSHR. However, when TSHR was 171 
co-expressed with the chimera LT receptor, hCG competed with TSH for binding, and 172 
desorption studies using radiolabelled TSH with ‘cold’ hCG suggested the presence of two 173 
binding sites per dimer, as opposed to a single binding pocket formed by the dimeric 174 
interaction of the two receptor protomers(32). This evidence suggests that GpHR dimers, and 175 
potentially oligomers are linked by strong negative cooperativity, with binding of ligand to one 176 
receptor protomer within the dimer, decreasing the binding affinity of ligand to the unbound 177 
receptor protomer. This important series of experiments demonstrate that GpHR display 178 
strong functional asymmetry via allosteric communication between protomers within a dimer 179 
and potentially oligomer(32).  180 
 181 
In subsequent follow-up studies the mode of communication between receptors within a dimer 182 
was explored. The transmembrane membrane was shown to mediate the allosteric 183 
communication between GpHR protomers in dimers(33), in line with previous reports and now 184 
accepted mode of allosteric communication between Class C GPCR dimers(12). Interestingly, 185 
homomers comprised of constitutively active receptors failed to display any evidence of 186 
negative cooperativity with symmetry in ligand binding observed(33). A question that remains 187 
is the link between negative cooperativity and preference of signal pathway activated and/or 188 
magnitude of signal response observed. For the related TSHR, it has been proposed that 189 
single receptor occupancy within a dimer is sufficient for Gs activation, but occupation of both 190 
receptor protomers is required for Gq activation (and can also mediate Gs activation(34). How 191 
negative cooperativity regulates ligand binding and subsequent G protein-signalling within an 192 
oligomer remains to be determined.  193 
 194 
5. Functional complementation of GpHR - roles in vitro and in vivo 195 
To explore the functional significance of GpHR dimers and oligomers, the phenomenon of 196 
functional complementation (also known as transactivation or intermolecular cooperation) has 197 
been exploited.  This experimental approach utilises the relatively compartmentalised nature 198 
of GPCR ligand binding and signal activation and has used to explore the impact of 199 
di/oligomerisation on the functions of number of GPCRs, including the GpHRs (reviewed by 200 
(35)). The structural properties of GpHRs make them a particularly good experimental model 201 
for utilising functional complementation to study di/oligomerisation, as ligand binding is largely 202 
mediated by the large extracellular N terminus domain of the receptors, and G protein coupling 203 
for signal propagation, by transmembrane domains 5-7, as evidenced by the naturally and 204 
experimentally induced activating and inactivating mutations of the GpHRs. Using these 205 
discrete functional properties, mutant GpHRs have been generated that are either ‘binding 206 
defective’- that cannot not bind to ligand but are theoretically still able to couple of G proteins, 207 
or ‘signal defective’ that can bind ligand but cannot couple to G protein(s) to generate 208 
intracellular signals, that if expressed by themselves are functionally inactive. Remarkably, 209 
when co-expressed, these mutant receptors undergo functional complementation, or trans-210 
activation, with the ‘signal defective’ receptor binding ligand, and the ‘binding defective’ 211 
receptor coupling to G protein. The functioning of these receptors can only occur via 212 
interaction of at least 1 signal- and 1 binding- defective receptor protomers within a complex, 213 
and thus restoration of functional response is via the formation of dimers and oligomers(35).  214 
This experimental paradigm has therefore proved a valuable and highly utilised model for 215 
studying the functional consequences of GpHR di/oligomerisation. 216 
 217 
In vitro aspects 218 
The ability of GpHRs to undergo functional complementation was first reported by Osuga et 219 
al(36). Using a mutant LHR that had previously been identified from a patient with Leydig cell 220 
hypoplasia that was shown to possess a premature stop codon at transmembrane domain 5, 221 
producing a truncated LHR, they showed that expression of this TM6/7 deleted LHR could 222 
bind hCG, but couldn’t activate cAMP production. To explore aspects of functional 223 
complementation, a chimeric FSHR/LHR, termed FLR, was generated, comprised of the 224 
FSHR extracellular domain and TM region of LHR, which generated cAMP in response to FSH 225 
(and not hCG)(36). Remarkably, when the FLR was co-expressed with the truncated mutant 226 
LHR and treated with hCG, cAMP production was observed, showing that the mutant LHR, 227 
that could bind hCG, but not activate cAMP production, had trans-activated the FLR. This 228 
showed that GpHRs could undergo functional complementation, via intermolecular 229 
communication and cross talk between these two receptor species(36), and most likely via the 230 
formation of dimers/oligomers.  231 
 232 
To explore the minimum TM domain requirements for transactivation to occur and how 233 
receptor protomers engaged in transactivation communicate, further deletions of the LHR 234 
were undertaken. It was found that co-expression of the LHR extracellular region fused to 235 
transmembrane domain 1 (TM1), with FLR was sufficient to mediate hCG-dependent 236 
cAMP(36). Interestingly, fusion of the LHR extracellular domain to the single membrane 237 
spanning CD8 peptide failed to mediate hCG dependent cAMP production, suggesting the 238 
requirement of transmembrane mediated inter-protomer communication for transactivation to 239 
occur(36). In contrast to this, other studies have shown that the extracellular domains of the 240 
GpHRs fused to CD8 or GPI to anchor to the extracellular region of the receptor to the plasma 241 
membrane were sufficient to mediate transactivation(37,38), and suggest a ‘kiss and run’ type 242 
interaction of the extracellular domain of one protomer directly interacting and activating 243 
neighbouring receptors. The latter view contrasts with our knowledge on how other GPCRs 244 
undergoing transactivation communicate and with more recent evidence in the GpHR field, 245 
whereby activation of neighbouring receptor protomers occurs via intermolecular 246 
communication via the TM bundles(12,28,30,33,39). Our own studies that have utilised a 247 
combination of single molecule imaging and molecular modelling would also suggest that 248 
dimerisation, and indeed oligomerisation of LHR undergoing functional complementation is via 249 
intermolecular communication between the TM bundles(31), showing the importance of inter 250 
protomer TM bundle cross talk in directing the functions of GpHR dimers and oligomers.  251 
 252 
Studies have shown that not all binding and signal defective mutant LHR and FSHR can 253 
undergo functional complementation(38,40), suggesting a specificity in pairing, and structural 254 
requirements for inter-protomer communication and ultimately transactivation to occur. The 255 
leucine rich repeats (LRR) of the extracellular region of LHR are essential for mediating ligand 256 
binding and appear to be a key factor in the facilitation of transactivation. It was found that 257 
binding defective mutant LHR with mutations that are localised to the LRR regions 1-3 were 258 
able to undergo functional complementation when co-expressed with signal defective LHR. 259 
However, if binding defective mutations were located to LRR regions 4-8, they were unable to 260 
undergo functional complementation(38,40). This most likely reflects the close proximity of 261 
LRR 4-8 to the hinge region of the LHR, which is crucial for transducing ligand binding to the 262 
TM region for signal activation. Additionally, as the hinge region also contains a suppressor of 263 
TM activation to constrain the unbound receptor in an inactive conformation, which on ligand 264 
binding is relaxed, mutations in LRR4-8, may interfere with the conformational changes that 265 
occur to allow TM activation, and thus transactivation fails to occur. 266 
 267 
Signal specificity of both LHR and FSHR has also been demonstrated using functional 268 
complementation. Co-expression of CD8 or GPI-anchored FSHR with differential signal 269 
defective mutant FSHR were shown to preferentially activate both cAMP and IP3, only cAMP, 270 
or only IP3(41), suggesting differential activational states and receptor conformations that 271 
mediate the specificity of G protein-coupling and subsequent intracellular pathway activation 272 
within dimers and oligomers. Our in vivo and in vitro studies studies utilising LHR 273 
transactivation mutations also support this idea(31), further details of which will be further 274 
discussed in latter sections. 275 
 276 
We would be remiss in admitting more atypical examples of GpHR transactivation within 277 
heteromers that has been observed. LHR has been shown to transactivate the epidermal 278 
growth factor receptor (EGFR), leading to the downregulation of ovarian aromatase 279 
expression during the LH surge during the ovarian cycle(42). In two different mouse models 280 
with inactivating mutations of the EGFR, it was shown that the down-regulation of the Cyp19a1 281 
via hCG (used to mimic the LH surge), was markedly impaired but not completely abolished, 282 
as it requires efficient signalling via transactivation of the EGFR.  The in vivo of LHR-mediated 283 
transactivation of the EGFR in ovulation has also been determined(43-45). 284 
 285 
In vivo aspects 286 
Most studies investigating the functional consequences of GPCR di/oligomerisation to date 287 
have primarily utilised in vitro approaches, which rely upon the over-expression of GPCRs in 288 
heterologous cell lines. As a result, the physiological consequence of GPCR di/oligomerisation 289 
remains poorly understood and our understanding is lacking in the physiological necessity and 290 
functional relevance of GPCR di/oligomerisation in vivo. A study that made significant inroads 291 
into proving the physiological relevance of Class A GPCR di/oligomerisation, utilised a 292 
functional complementation approach and the LHR as a model GPCR, to determine if LHR 293 
di/oligomerisation was sufficient to mediate LHR functions in vivo. Using the LHR knockout 294 
(LuRKO) mice, and a BAC transgenic approach, targeted co-expression of ligand binding 295 
defective LHR (C22A mutation, LHRB-) with signal defective mutant LHR (a deletion of 296 
transmembrane domains 6 and 7, LHRS-) could rescue the hypogonadal phenotype of male 297 
LuRKO mice(46). Testes size and serum testosterone levels were equivalent to that of wild 298 
type litter mates. Importantly, the infertile phenotype of LuRKO animals was also reversed, 299 
with litter frequency and sizes from mating studies in LuRKO mice co-expressing LHRB- and 300 
LHRS- equivalent to wild type littermates(46). Serum LH was slightly raised in comparison to 301 
wild type littermates, showing the increased hypothalamic-pituitary drive to the testes to initiate 302 
and maintain LH-dependent testosterone production. This seminal study showed the first in 303 
vivo, physiological evidence for GPCR di/oligomerisation, and importantly, that 304 
di/oligomerisation was a functionally relevant mode of LHR activation/signal propagation in 305 
vivo(46). Although there has been a subsequent in vitro study that critically debated whether 306 
the observations of this in vivo study were due to idiosyncrasies of the BAC transgenic method 307 
for introducing the LHRB- and LHRS- mutants into the LuRKO mouse background(47), the 308 
control experiments from this study conclusively showed that the expression of single LHRB- 309 
or LHRS- mutants failed to rescue the infertile and hypogonadal phenotype of these mice(46). 310 
Thus, confirming the specificity of the BAC approach, and confidence in LHR functional 311 
complementation occurring in male mice in vivo. Interestingly, co-expression of LHRB- and 312 
LHRS- in female LuRKO mice, failed to rescue the infertile and hypogonadal phenotype of 313 
these animals. This may reflect the low levels of LHRB- and LHRS- expression female mice, 314 
and the inability to induce sufficient LHR expression during the ovarian cycle. It may also 315 
additional reflect the inability of functional complementation to mediate the multiple signalling 316 
and functional requirements of LHR in females, as previously discussed. Further insights as 317 
to why the latter proposition may be the case, will be discussed in the next section.  318 
 319 
6. Single molecule imaging of gonadotrophin receptor dimerisheteroation 320 
The advances in technology development have resulted in an explosion of single molecule 321 
imaging and single particle tracking techniques. These advances have given unprecedented 322 
insight into the nature and composition of GpHR homomers and heteromers, and the link with 323 
signal activation.   324 
 325 
Early insights into the membrane organisation of LHR were provided by single particle tracking 326 
studies, which presented evidence of rat LHR localising to small specialised membrane 327 
microdomains, or lipid rafts, following binding of hCG(48). These microdomains were 328 
approximately 3 times smaller than unbound receptor, and importantly, when disrupted using 329 
the cholesterol depleting agent, methyl--cyclodextrin, showed a decreased hCG-dependent 330 
cAMP production(48). As a total abrogation of hCG-dependent cAMP production was not 331 
observed, it suggests that localisation of hCG-bound LHR to lipid rafts is not essential for Gs 332 
coupling. In support of this, although constitutively active mutant LHR also localised to lipid 333 
rafts, and these LHR microdomains were approximately the same size as hCG-bound LHR, 334 
cAMP production was not affected by raft disruption using methyl--cyclodextrin(49). That 335 
said, the relationship between raft location and coupling of LHR to alternate G protein-336 
dependent and independent pathways remains unknown. Additionally, whether ligand-specific 337 
differences in raft localisation and/or size of these microdomains exist.  This may be 338 
particularly pertinent given the changing lipid environment, and LH/hCG/LHR signal 339 
requirements of the ovarian follicle during folliculogenesis and corpus luteum function.   340 
 341 
A recent study utilising a combination of precision FRET and fluorescent correlation 342 
spectroscopy with photon counting histogram methods, has explored the nature and 343 
composition of FSHR homomers within the plasma membrane. Using a fusion of a C tail-344 
truncated human FSHR, the C terminus tail of the LHR and fluorescent proteins compatible 345 
with FRET to the proximal end of the C-tail, FSHR was shown to traffick to and reside in the 346 
plasma membrane almost exclusively as homodimers(50). These findings contrast with 347 
previous crystal structure analysis of the FSHR ectodomain and hinge region, which proposed 348 
that FSHR exists as trimers(51). However, the crystal structures lack the vital interactions of 349 
the extracellular and transmembrane domain, due to complexities of generating stable crystals 350 
with intact transmembrane domains. Additionally, the functional and physiological significance 351 
of different FSHR complexes remains to be determined.   352 
 353 
Our recent studies have provided significant insight into how the composition and functional 354 
role of each protomer within an LHR oligomer can regulate signal amplitude. Utilising a 355 
functional complementation approach, and the same functional complementation LHRB- and 356 
LHRS- from our previously discussed in vivo study, we employed the super resolution imaging 357 
approach of photoactivated dye, localisation microscopy (PD-PALM), to quantitate the number 358 
of LHR monomer, dimers and oligomers at the plasma membrane, and determine the nature 359 
of these complexes. Using heterologous cell lines that stably expressed either the wild type 360 
mouse LHR, or co-expressing LHRB- and LHRS- mutant receptors, we observed that 361 
approximately 40% of LHR formed homomers, with remaining 60% residing as monomers(31). 362 
Sub-analysis of the types of associated LHR complexes that were observed revealed that the 363 
predominant associated form of wild type LHR was dimers, with a small number of lower order 364 
and higher order wild type LHR complexes. In contrast, in cells co-expressing LHRB- and 365 
LHRS, approximately half the number of dimers were observed, with a concomitant increase 366 
in lower order trimers and tetramers(31). Interestingly, treatment with LH or hCG had no effect 367 
on the number of associated wild type or functional complementation LHR, nor the types of 368 
oligomeric complexes formed, in line with previous findings from BRET analysis(28). 369 
Assessment of LH and hCG-dependent Gs and Gq-association in wild type LHR and functional 370 
complementation models, revealed that LH-dependent Gq activation was impaired in the 371 
functional complementation model, suggesting that for full LH-dependent Gq activation, an 372 
element of cis or unidirectional activation of LHR is required(31). This may shed light as to 373 
why the female functional complementation mutant mice were infertile, as previously studies 374 
have shown LH-dependent Gq activation is required for ovulation(52). Generation of cell lines 375 
with varying cell surface ratios of LHRB-:LHRS- revealed that cells with an excess of LHRS-376 
:LHRB- resulted in amplification of Gs and Gq-dependent signals. Interestingly, the difference 377 
in Gs and Gq signal observed, corresponded with an enrichment of LHRB- receptor protomers 378 
in both trimers and tetramers, suggesting, that modulation of specific the composition and 379 
functional role adopted by a protomer engaged in an oligomeric complex, can fine tune the 380 
amplitude of signal response generated.  381 
 382 
7. Gonadotrophin receptor heteromers 383 
The formation of LHR/FSHR heteromers has long been a debated topic. With specific 384 
relevance to female reproductive physiology, LHR and FSHR are co-expressed within 385 
granulosa cells of the dominant pre-ovulatory follicle, suggesting a functional role for LHR-386 
FSHR crosstalk in mediating/facilitating ovulation.  As such, heteromerisation of LHR/FSHR 387 
was first demonstrated by BRET(53), and subsequently by fluorescent correlation 388 
spectroscopy(50), using heterologous cell models, co-expressing LHR and FSHR. 389 
Importantly, heteromerisation of LHR/FSHR was shown to alter the pharmacology of FSHR 390 
and LHR, enhancing dissociation of bound ligands, and negatively impacting on Gs-391 
dependent signal pathway activation(53). As LHR is known to signal via both Gs and Gq-392 
dependent pathways, with the latter particularly important for mediating LH-dependent 393 
ovulatory events(52), studies by our group further investigated the impact of LHR/FSHR on 394 
LH-dependent Gq activation. We found a change from a transient to more sustained calcium 395 
signal, that was both dependent on Gq activation and influx of extracellular calcium(54). 396 
Importantly, the presence of a sustained calcium response was also confirmed in human 397 
granulosa lutein cells, which endogenously co-express LHR and FSHR, which was also found 398 
to be sensitive to extracellular calcium channel blockers. PD-PALM studies revealed an LH-399 
dependent increase in LHR/FSHR heteromerisation, with specific enrichment in 400 
heterotetramers, suggesting that modulation of LHR/FSHR heteromers mediated the switch 401 
from transient to sustained LH-dependent calcium signalling(54). Investigation of cross-talk 402 
between LH/hCG and FSH has shown that co-treatment of FSH with either LH or hCG results 403 
in potentiation of their respective effects on apoptosis and steroidogenesis(55), giving an 404 
insight into the potential physiological roles of LHR/FSHR heteromers. However, 405 
understanding the exact physiological role of LHR/FSHR heteromers in vivo, remains to be 406 
determined.  407 
 408 
8. Perspectives and conclusions 409 
It is unquestionable that GpHRs can associate to form homomers and heteromers. The 410 
formation of homomers and heteromers has been shown to impact on aspects of GpHR 411 
pharmacology, including ligand binding, signal specificity and signal magnitude. Despite the 412 
overwhelming experimental evidence detailing the functional relevance of GpHR 413 
di/oligomerisation, limitations in probing FSHR and LHR in vivo coupled with the technical 414 
complexities, e.g., the lack of specific FSHR and LHR antibodies, mean that our knowledge of 415 
the physiological roles of these receptor complexes remains limited. However, with the relative 416 
ease and decreasing cost of gene modification techniques such as CRISPR, future research 417 
programs in this area will enhance our knowledge to gain insight into the physiological role(s) 418 
of GpHR homomers and heteromers.   419 
 420 
With technological advances, come questions. The intriguing finding from the single molecule 421 
imaging studies of LHR that 60% of LHR at the plasma membrane appears to be 422 
monomers(31), suggests a distinct functional role for monomers in mediating/regulating LHR 423 
functions. Indeed, deciphering how different ‘flavours’ of GpHR monomers, homomers and 424 
heteromers regulate gonadotrophin hormone functions will provide much needed insight into 425 
how these distinct receptor complexes regulate and fine-tune GpHR functions in vitro and 426 
importantly, in vivo. Identifying the unique ‘signatures’ of GpHR complexes at the cell surface, 427 
the drivers which control the formation of these complexes, and the resulting cellular 428 
responses, will provide invaluable insight into how GpHR di/oligomerisation impacts 429 
reproductive health, and potential dysregulation in disease. Such advances will provide the 430 
opportunity for novel and potentially personalised pharmacological treatment strategies for 431 
treatment reproductive pathologies, and may lead to advances for the improvement in the 432 
success rate of assisted reproductive technologies.   433 
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